MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President, Clinical...

MAP Pharmaceuticals Appoints Donald J. Kellerman Senior Vice President,
Clinical Development and Medical Affairs

MOUNTAIN VIEW, Calif., July 23 /PRNewswire-FirstCall/ -- MAP
Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of Donald
J. Kellerman, Pharm.D. to the position of Senior Vice President, Clinical
Development and Medical Affairs.
Dr. Kellerman brings to MAP Pharmaceuticals more than 25 years of clinical
experience, serving as project leader for multiple products including
Flovent(R), Advair(R) and Xopenex(R). Most recently, Dr. Kellerman was Senior
Vice President of Development at Inspire Pharmaceuticals, Inc., where he was
responsible for all aspects of drug development, including clinical research,
regulatory affairs, project management and biostatistics. He also led groups
responsible for running several clinical programs in the respiratory,
ophthalmology and cardiovascular areas. Prior to joining Inspire, Dr.
Kellerman held positions at Glaxo Wellcome, Sepracor, Inc. and Ciba-Geigy
Corporation. During his tenure at Glaxo Wellcome, Dr. Kellerman held numerous
positions, including Director, Respiratory Clinical Research, and managed the
clinical development of inhaled corticosteroids for the treatment of asthma in
his role as project leader for Flovent, from first U.S. clinical studies
through approval. At Sepracor he led the team responsible for filing the new
drug application for Xopenex, an inhaled beta2-agonist used to treat asthma
and chronic obstructive pulmonary disease (COPD).
In his new role with MAP Pharmaceuticals, Dr. Kellerman will be
responsible for overseeing strategy and execution of MAP Pharmaceuticals'
clinical programs including Phase 3 clinical trials for UDB for the potential
treatment of pediatric asthma, and for MAP0004 for the potential treatment of
migraine.
"MAP Pharmaceuticals is pleased to welcome Don Kellerman to the executive
management team at such a pivotal point in our company's history," said
Timothy S. Nelson, President and Chief Executive Officer of MAP
Pharmaceuticals. "The depth and breadth of Don's experience successfully
moving product candidates through various stages of clinical development, FDA
approval and product launch will serve the company well as we pursue our goals
of commercializing UDB and MAP0004."
Kellerman received his Bachelor of Science and Doctor of Pharmacy from the
College of Pharmacy at the University of Minnesota. He has lead or
co-authored over 80 publications related to the development of pharmaceutical
products.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals develops and plans to commercialize new therapies for
children and adults who suffer from chronic conditions that it believes are
not adequately treated by currently available medicines. The company applies
its proprietary inhalation technologies to enhance the therapeutic benefits
and commercial attractiveness of proven drugs while minimizing risk by
capitalizing on their known safety, efficacy and commercialization history.
MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit
Dose Budesonide is being developed for the potential treatment of pediatric
asthma, and MAP0004 is being developed for the potential treatment of
migraine. MAP Pharmaceuticals' pipeline also includes a drug candidate in
early clinical development for the treatment of asthma and chronic obstructive
pulmonary disease.
Additional information about MAP Pharmaceuticals can be found at
http://www.mappharma.com.
Forward-Looking Statements
In addition to statements of historical facts or statements of current
conditions, this press release contains forward-looking statements, including
with respect to product candidates in clinical development. Actual results may
differ materially from current expectations based on risks and uncertainties
affecting MAP Pharmaceuticals' business, including, without limitation, risks
and uncertainties relating to the development, clinical testing and potential
commercialization of MAP Pharmaceutical's lead product candidates. The reader
is cautioned not to unduly rely on the forward-looking statements contained in
this press release. MAP Pharmaceuticals expressly disclaims any intent or
obligation to update these forward-looking statements, except as required by
law. Additional information on potential factors that could affect MAP
Pharmaceuticals' results and other risks and uncertainties are detailed in its
Quarterly Report on Form 10-Q, filed with the SEC on May 14, 2008, and
available at http://edgar.sec.gov.
SOURCE MAP Pharmaceuticals, Inc.

Mariesa Kemble of WeissComm Partners, +1-608-850-4745, mkemble@wcpglobal.com,
for MAP Pharmaceuticals, Inc.